Epstein–Barr virus in the ethnic Tatars population: the infection and sequence variants of LMP1 oncogene

Cover Page

Cite item

Full Text

About the authors

K. V. Smirnova

Research Institute of Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia;
Pirogov National Research Medical University, Ministry of Health of Russia

Author for correspondence.
Email: skv.lab@yandex.ru
ORCID iD: 0000-0001-6209-977X
Russian Federation

N. B. Senyuta

Research Institute of Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0001-8915-8274
Russian Federation

I. V. Botezatu

Research Institute of Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0002-0297-4963
Russian Federation

T. E. Dushenkina

Research Institute of Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: fake@neicon.ru
Russian Federation

A. K. Lubenskaya

Research Institute of Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: fake@neicon.ru
Russian Federation

A. A. Frolovskaya

Research Institute of Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: fake@neicon.ru
Russian Federation

S. V. Petrov

Republican Clinical Oncological Dispensary, Ministry of Health of the Republic of Tatarstan

Email: fake@neicon.ru
Russian Federation

A. V. Lichtenstein

Research Institute of Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0002-0190-5069
Russian Federation

V. E. Gurtsevitch

Research Institute of Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0003-1840-4364
Russian Federation

References

  1. Fujiki H., Watanabe T., Suganuma M. Cell-sufaсe nucleolin acts as a central mediator for carcinogenic, anti-carcinogenic, and disease-related ligands. J Cancer Res Clin Oncol 2014;140(7):689–99. doi: 10.1007/s00432-014-1587-5. PMID: 24469254.
  2. Koutsioumpa M., Papadimitriou E. Cellsuface nucleolin as a target for anti-cancer therapies. Recent Part Anticancer Drug Discov 2018;9(2):137–52. PMID: 24251811.
  3. Lushnikova A., Ponkratova D., Andreev S. et al. A рossibility for therapy of metastatic cutaneous melanoma with cationic peptides. Eur J Cancer 2017;72(Sl): 127–28.
  4. Lushnikova A.A., Ponkratova D.A., Rudakova A.A. et al. The mechanisms of antitumor toxicity in a number of cationic peptides. Modern Science 2017;11:124–6.
  5. Lushnikova A.A., Ponkratova D.A., Morozova L.F., Andreev S.M. Induction of apoptosis in cutaneous melanoma cells by cationic peptides. Int Sci J 2017;7– 2(61):75–9.
  6. Dang W., Muto Y., Inoue Y. et al. RCSB PDB TI Solution structure of the RRM_1domain of NCL protein. FAUCRDT 2005;12(12). Available at: http://www.rcsb.org/structure/2FC8.
  7. Kellenberger E., Rodrigo J., Muller P., Rognan D. Comparative evaluation of eight docking tools for docking and virtual screening accuracy. Proteins 2004;57(2):225–42. doi: 10.1002/prot. 20149. PMID: 15340911.
  8. Site Map User Manual. Schrödinger: LLC. Schrödinger Press, 2009.
  9. Glide User Manual. Schrödinger: LLC. Schrödinger Press, 2015.
  10. Induced Fit Docking. Schrödinger: LLC. Schrödinger Press, 2009.
  11. Du X., Li Y., Xia Y.L. et al. Insights into protein-ligand interactions: mechanisms, models, and methods. Int J Mol Sci 2016;17(2):144–78. doi: 10.3390/ijms17020144. PMID: 26821017.
  12. Balça-Silva J., do Carmo A., Täo H. et al. Nucleolin is expressed in patient-derived samples and glioblastoma cells, enabling improved intracellular drug delivery and cytotoxicity. Exp Cell Res 2018;370(1): 68–77. doi: 10.1016/j.yexcr.2018.06.005. PMID: 29902537.encoded latent membrane protein LMP1 are required for transformation of rat-1 fibroblasts. J Virol 1993;67(3):1638–46. PMID: 8382313.
  13. Kulwichit W., Edwards R.H., Davenport E.M. et al. Expression of the Epstein–Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci USA 1998;95(20):11963–8. PMID: 9751773.
  14. Hu L.F., Zabarovsky E.R., Chen F. et al. Isolation and sequencing of the Epstein– Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma. J Gen Virol 1991;72(Pt 10):2399–409. doi: 10.1099/0022-1317-72-10-2399. PMID: 1681026.
  15. Blake S.M., Eliopoulos A.G., Dawson C.W., Young L.S. The transmembrane domains of the EBV-encoded latent membrane protein 1(LMP1) variant CAO regulate enhanced signalling activity. Virology 2001;282(2):278–87. doi: 10.1006/viro.2001.0828. PMID: 11289810.
  16. Farrell P.J. Signal transduction from the Epstein–Barr virus LMP-1 transforming protein. Trends Microbiol 1998;6(5):175–7. PMID: 9614338.
  17. Huen D.S., Henderson S.A., Croom-Carter D., Rowe M. The Epstein–Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 1995;10(3):549–60. PMID: 7845680.
  18. Dirmeier U., Neuhierl B., Kilger E. et al. Latent membrane protein 1 is critical for efficient growth transformation of human B cells by epstein-barr virus. Cancer Res 2003;63(11):2982–9. PMID: 12782607.
  19. Edwards R.H., Seillier-Moiseiwitsch F., Raab-Traub N. Signature amino acid changes in latent membrane protein 1 distinguish Epstein–Barr virus strains. Virology 1999;261(1):79–95. doi: 10.1006/viro.1999.9855. PMID: 10441557.
  20. Feederle R., Klinke O., Kutikhin A. et al. Epstein–Barr virus: from the detection of sequence polymorphisms to the recognition of viral types. Curr Top Microbiol Immunol 2015;390(Pt 1):119–48. doi: 10.1007/978-3-319-22822-8_7. PMID: 26424646.
  21. Neves M., Marinho-Dias J., Ribeiro J., Sousa H. Epstein–Barr virus strains and variations: geographic or disease-specific variants? J Med Virol 2017;89(3):373–87. doi: 10.1002/jmv.24633. PMID: 27430663.
  22. Gurtsevitch V.E., Iakovleva L.S., Shcherbak L.N. et al. The LMP1 oncogene sequence variations in patients with oral tumours associated or not associated with the Epstein–Barr. Mol Biol (Mosk) 2013;47(6):987–95. PMID: 25509860.
  23. Hahn P., Novikova E., Scherback L. et al. The LMP1 gene isolated from Russian nasopharyngeal carcinoma has no 30-bp deletion. Int J Cancer 2001;91(6):815–21. PMID: 11275985.
  24. Miller W.E., Edwards R.H., Walling D.M., Raab-Traub N. Sequence variation in the Epstein–Barr virus latent membrane protein 1. J Gen Virol 1994;75(Pt 10):2729–40. doi: 10.1099/0022-1317-75-10-2729. PMID: 7931159.
  25. Lawrence J.B., Villnave C.A., Singer R.H. Sensitive, high-resolution chromatin and chromosome mapping in situ: presence and orientation of two closely integrated copies of EBV in a lymphoma line. Cell 1988;52(1):51–61. PMID: 2830981.
  26. Lo Y.M., Chan L.Y., Lo K.W. et al. Quantitative analysis of cell-free Epstein– Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999;59(6):1188–91. PMID: 10096545.
  27. Botezatu I.V., Kondratova V.N., Shelepov V.P., Lichtenstein A.V. DNA melting analysis: application of the “open tube” format for detection of mutant KRAS. Anal Biochem 2011;419(2):302–8. doi: 10.1016/j.ab.2011.08.015. PMID: 21889482.
  28. Senyuta N., Yakovleva L., Goncharova E. et al. Epstein–Barr virus latent membrane protein 1 polymorphism in nasopharyngeal carcinoma and other oral cavity tumors in Russia. J Med Virol 2014;86(2): 290–300. doi: 10.1002/jmv.23729. PMID: 24009107.
  29. Li H.P., Chang Y.S. Epstein–Barr virus latent membrane protein 1: structure and functions. J Biomed Sci 2003;10(5):490– 504. doi: 10.1159/000072376. PMID: 12928589.
  30. Kanai K., Satoh Y., Saiki Y. et al. Difference of Epstein–Barr virus isolates from Japanese patients and African Burkitt’s lymphoma cell lines based on the sequence of latent membrane protein 1. Virus Genes 2007;34(1):55–61. doi: 10.1007/s11262-006-0010-y. PMID: 16917741.
  31. Wilmes E., Wolf H., Haus M. Tonsillar cancer and Epstein–Barr virus. Laryngol Rhinol Otol (Stuttg) 1983;62(12):586–9. PMID: 6323895.
  32. Wu L.Y., Cheng J., Lu Y. et al. Epstein– Barr virus infection in benign lymphoepithelial lesions with malignant transformation of salivary glands. Zhonghua Kou Qiang Yi Xue Za Zhi 2004;39(4):291–3. PMID: 15454012.
  33. Ayadi W., Khabir A., Hadhri-Guiga B. et al. North African and Southeast Asian nasopharyngeal carcinomas: between the resemblance and the dissemblance. Bull Cancer 2010;97(4):475–82. doi: 10.1684/bdc.2010.1090. PMID: 20385521.
  34. Namikawa T., Fujisawa K., Munekage E. et al. Epstein–Barr virus-associated early gastric carcinoma with lymphoid stroma, accompanied with lymph node metastasis. Mol Clin Oncol 2018;8(4):561–6. doi: 10.3892/mco.2018.1567. PMID: 29541465.
  35. Alexander F.E., Jarrett R.F., Lawrence D. et al. Risk factors for Hodgkin’s disease by Epstein–Barr virus (EBV) status: prior infection by EBV and other agents. Br J Cancer 2000;82(5):1117–21. doi: 10.1054/bjoc.1999.1049. PMID: 10737396.
  36. Andreone P., Gramenzi A., Lorenzini S. et al. Posttransplantation lymphoproliferative disorders. Arch Intern Med 2003;163:1997–2004. DOI: 10.1001/ archinte.163.17.1997. PMID: 14504111.
  37. State of oncological care in Russia in 2016. Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS” Minzdrava Rossii, 2017. 236 p. (In Russ.).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 57560 от  08.04.2014.